Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

466 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The novel butyrate derivative phenylalanine-butyramide protects from doxorubicin-induced cardiotoxicity.
Russo M, Guida F, Paparo L, Trinchese G, Aitoro R, Avagliano C, Fiordelisi A, Napolitano F, Mercurio V, Sala V, Li M, Sorriento D, Ciccarelli M, Ghigo A, Hirsch E, Bianco R, Iaccarino G, Abete P, Bonaduce D, Calignano A, Berni Canani R, Tocchetti CG. Russo M, et al. Among authors: napolitano f. Eur J Heart Fail. 2019 Apr;21(4):519-528. doi: 10.1002/ejhf.1439. Epub 2019 Mar 6. Eur J Heart Fail. 2019. PMID: 30843309 Free article.
Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review.
Napolitano F, Formisano L, Giardino A, Girelli R, Servetto A, Santaniello A, Foschini F, Marciano R, Mozzillo E, Carratù AC, Cascetta P, De Placido P, De Placido S, Bianco R. Napolitano F, et al. Cancers (Basel). 2019 Jul 13;11(7):981. doi: 10.3390/cancers11070981. Cancers (Basel). 2019. PMID: 31337045 Free PMC article.
Mechanisms of resistance to mTOR inhibitors.
Formisano L, Napolitano F, Rosa R, D'Amato V, Servetto A, Marciano R, De Placido P, Bianco C, Bianco R. Formisano L, et al. Among authors: napolitano f. Crit Rev Oncol Hematol. 2020 Mar;147:102886. doi: 10.1016/j.critrevonc.2020.102886. Epub 2020 Jan 29. Crit Rev Oncol Hematol. 2020. PMID: 32014673 Review.
A review of the use of next generation sequencing methodologies to identify biomarkers of resistance to CDK4/6 inhibitors in ER+/HER2- breast cancer.
Servetto A, Napolitano F, De Angelis C, De Placido P, Giuliano M, Arpino G, De Placido S, Bianco R, Formisano L. Servetto A, et al. Among authors: napolitano f. Crit Rev Oncol Hematol. 2021 Jan;157:103191. doi: 10.1016/j.critrevonc.2020.103191. Epub 2020 Dec 9. Crit Rev Oncol Hematol. 2021. PMID: 33309572 Review.
Use of FOLFIRINOX or Nab-Paclitaxel Plus Gemcitabine for the Treatment of Locally Advanced Pancreatic Adenocarcinoma: A Single Institution Observational Study.
Servetto A, Santaniello A, Napolitano F, Foschini F, Marciano R, Mozzillo E, Cascetta P, Amato AR, Augurio MR, Maresca L, De Placido P, De Placido S, Formisano L, Bianco R. Servetto A, et al. Among authors: napolitano f. Cancers (Basel). 2021 Sep 30;13(19):4939. doi: 10.3390/cancers13194939. Cancers (Basel). 2021. PMID: 34638422 Free PMC article.
Inadequate health-related quality of life assessment and reporting in phase III clinical trials of immune checkpoint inhibitors in solid cancers: A systematic review.
Servetto A, Salomone F, Di Costanzo F, Iuliano R, Marandino L, Napolitano F, Santaniello A, De Placido P, De Placido S, Di Maio M, Formisano L, Bianco R. Servetto A, et al. Among authors: napolitano f. Crit Rev Oncol Hematol. 2022 Apr;172:103649. doi: 10.1016/j.critrevonc.2022.103649. Epub 2022 Mar 5. Crit Rev Oncol Hematol. 2022. PMID: 35259486 Review.
466 results